STARLIX

LOE Approaching

nateglinide

NDAORALTABLET
Approved
Dec 2000
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
8

Clinical Trials (5)

NCT01316107Phase 3Completed

A Study to Assess Safety and Efficacy of ASP1941 in Combination With Nateglinide in Type 2 Diabetic Patients

Started Jan 2011
122 enrolled
Type 2 Diabetes Mellitus
NCT01030952Phase 4Completed

Effects of Nateglinide on Postprandial Glucose Excursion by Restoring Early Phase Insulin Secretion

Started Dec 2009
103 enrolled
Diabetes Mellitus, Type 2
NCT00928889Phase 4Completed

Effects of Nateglinide vs Acarbose on Postprandial Glucose Fluctuation, Dyslipidemia, and Inflammatory Factors

Started Jul 2009
160 enrolled
Diabetes Mellitus, Type 2
NCT00437918Phase 4Completed

The Effects of Nateglinide and Acarbose on the Post-Prandial Glucose Control in Type 2 Diabetic Patients

Started Jan 2007
85 enrolled
Diabetes MellitusType 2 Diabetes Mellitus
NCT00402909Phase 4Completed

Safety and Efficacy of Nateglinide in Patients With Type 2 Diabetes Already Taking Insulin Glargine, Metformin and/or Pioglitazone or Rosiglitazone

Started Nov 2006
28 enrolled
Type 2 Diabetes
Data Sources
  • Drug label: DailyMed / FDA
  • Clinical trials: ClinicalTrials.gov
  • Patent data: FDA Orange Book
  • Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.